Skip to main content

Table 1 Demographic and clinical characteristics of UC patients

From: Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience

Characteristics

All patients n = 33

Sex (men/women), n (%)

20 (60.6)/13 (39.4)

Age (years)*

43.2 ± 17.4

Disease duration (years)*

7.0 ± 5.7

Modified Truelove and Witts severity index*

9.4 ± 3.2

Mayo score (endoscopy)*

2.8 ± 0.4

Extent of disease

 

  Left-side type, n (%)

13 (39.4)

  Extensive colitis, n (%)

20 (60.6)

Concomitant medications

 

  5-ASA formulation, n (%)

29 (87.9)

  Corcicosteroids, n (%)

11 (33.3)

  Azathioprine/Mercaptopurine, n (%)

16 (48.5)

  Tacrolimus, n (%)

13 (39.4)

Cytomegalovirus, n (%)

11 (33.3)

  1. IFX: infliximab, 5-ASA: 5-aminosalicylic acid.
  2. Results reported as number (%) of patients or as *mean ± standard deviation.